Lipocine presents LPCN 2401 Phase 2 data at ObesityWeek showing improved body composition and liver health

Lipocine Inc.

In Phase 2 trial, LPCN 2401 increased lean mass, reduced fat mass, and improved fat-to-lean ratio vs placebo at 20 and 36 weeks.
Treatment with LPCN 2401 showed rapid reductions in liver fat content and liver injury markers (ALT, AST) starting at 4-8 weeks.
MRI-PDFF demonstrated significant reductions in liver fat at 12 weeks, maintained through week 36.
LPCN 2401 was well tolerated with no concerning safety signals observed through 72 weeks of exposure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.